Bristol’s Pfizer, AstraZeneca Deals Could Add Up To $2 Billion To R&D Budget

Bristol-Myers Squibb's partnerships with AstraZeneca and Pfizer to develop several late-stage compounds may provide the company with $2 billion to support its research and development initiatives, the firm said

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet